OBJECTIVES: The aim of this study was to investigate the prognostic significance of elevated white blood cell (WBC) count at the time of the diagnosis of cervical cancer recurrence. METHODS: The baseline characteristics and outcome data of 219 patients who had a diagnosis of recurrent cervical cancer between April 1996 and September 2010 were collected and reviewed. Survival after recurrence was compared between the leukocytosis group (WBC ≥9000/μL) and the nonleukocytosis group (WBC <9000/μL). A Cox proportional hazards regression model was used to investigate the prognostic significance of elevated WBC count in patients with recurrent cervical cancer. RESULTS: The patients in the leukocytosis group showed significantly shorter disease-free interval (P = 0.0005) and more frequently had multiple recurrences (P = 0.0101) than those in the nonleukocytosis group. The median survival after recurrence of the patients with elevated WBC count was 9 months, which was significantly shorter than the 21 months observed in the patients without normal WBC count (log rank; P < 0.0001). Multivariate analyses revealed that clinical stage, tumor diameter, histology, an elevated WBC count (≥9000/μL), and an elevated neutrophil count (≥6500/μL) were significant prognostic factors in survival after recurrence. CONCLUSION: The elevated WBC count at the time of the diagnosis of recurrence is an independent prognostic factor in patients with recurrent cervical cancer.
OBJECTIVES: The aim of this study was to investigate the prognostic significance of elevated white blood cell (WBC) count at the time of the diagnosis of cervical cancer recurrence. METHODS: The baseline characteristics and outcome data of 219 patients who had a diagnosis of recurrent cervical cancer between April 1996 and September 2010 were collected and reviewed. Survival after recurrence was compared between the leukocytosis group (WBC ≥9000/μL) and the nonleukocytosis group (WBC <9000/μL). A Cox proportional hazards regression model was used to investigate the prognostic significance of elevated WBC count in patients with recurrent cervical cancer. RESULTS: The patients in the leukocytosis group showed significantly shorter disease-free interval (P = 0.0005) and more frequently had multiple recurrences (P = 0.0101) than those in the nonleukocytosis group. The median survival after recurrence of the patients with elevated WBC count was 9 months, which was significantly shorter than the 21 months observed in the patients without normal WBC count (log rank; P < 0.0001). Multivariate analyses revealed that clinical stage, tumor diameter, histology, an elevated WBC count (≥9000/μL), and an elevated neutrophil count (≥6500/μL) were significant prognostic factors in survival after recurrence. CONCLUSION: The elevated WBC count at the time of the diagnosis of recurrence is an independent prognostic factor in patients with recurrent cervical cancer.
Authors: Audrey E Kam; Gopichand Pendurti; Umang H Shah; Mohammad H Ghalib; Imran Chaudhary; Jennifer Chuy; Lakshmi Rajdev; Andreas Kaubisch; Santiago Aparo; Ioannis Mantzaris; Sanjay Goel Journal: Invest New Drugs Date: 2018-10-12 Impact factor: 3.850
Authors: Aaron Denson; Nancy Burke; Georgine Wapinsky; Barbara Bertels; Tzu-Hua Juan; Jae Lee; Gregory M Springett; Jonathan R Strosberg; Richard D Kim; Dan M Sullivan; Amit Mahipal Journal: Am J Clin Oncol Date: 2018-02 Impact factor: 2.339
Authors: Tim De Schutter; Graciela Andrei; Dimitri Topalis; Sophie Duraffour; Tania Mitera; Joost van den Oord; Patrick Matthys; Robert Snoeck Journal: Mol Cancer Date: 2013-12-10 Impact factor: 27.401
Authors: Mazen A Juratli; Yulian A Menyaev; Mustafa Sarimollaoglu; Eric R Siegel; Dmitry A Nedosekin; James Y Suen; Alexander V Melerzanov; Tareq A Juratli; Ekaterina I Galanzha; Vladimir P Zharov Journal: PLoS One Date: 2016-05-26 Impact factor: 3.240